SCHEMBL709260

SCHEMBL709260

CCN(CC)S(=O)(=O)c1ccc(C(=O)c2cc(CC(=O)O)cc3ccc(F)cc23)cc1

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PTGDR2 Q9Y5Y4 10/20 0.58
TAS2R14 Q9NYV8 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
ALDH1A1 P00352 1/20 0.40
LMNA P02545 1/20 0.40
TP53 P04637 1/20 0.39
THRB P10828 1/20 0.39
CA12 O43570 1/20 0.39
CA2 P00918 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CA9 Q16790 1/20 0.39
SLC22A6 Q4U2R8 1/20 0.39
SLC22A8 Q8TCC7 1/20 0.39
ABCC2 Q92887 1/20 0.39
SLC22A12 Q96S37 1/20 0.39
UGT1A7 Q9HAW7 1/20 0.39
SLC22A11 Q9NSA0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13286612 0.94 PTGDR2 (0.52) PTGDR2MEN1KMT2ALMNACA12
SCHEMBL709616 0.90 PTGDR2 (0.46) PTGDR2ALDH1A1RAB9A
SCHEMBL708181 0.87 PTGDR2 (0.46) PTGDR2TP53THRB
SCHEMBL709910 0.86 PTGDR2 (0.54) PTGDR2
SCHEMBL709826 0.84 PTGDR2 (0.46) PTGDR2
SCHEMBL711547 0.84 PTGDR2 (0.45) PTGDR2CA2CA9
SCHEMBL13354022 0.82 PTGDR2 (0.50) PTGDR2ALDH1A1LMNASMN1; SMN2
SCHEMBL710040 0.79 PTGDR2 (0.45) PTGDR2
SCHEMBL709881 0.79 PTGDR2 (0.58) PTGDR2ALDH1A1LMNASMN1; SMN2
SCHEMBL711932 0.78 PTGDR2 (0.46) PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US claimed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 US claimed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-8124629-B2 Naphthylacetic acids HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 US disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 US disclosed
US-20100137250-A1 NAPHTHYLACETIC ACIDS FIROOZNIA FARIBORZ 2010-06-03 US disclosed
WO-2010055005-A1 NAPHTHYLACETIC ACIDS F. HOFFMANN-LA ROCHE AG (CH) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137250-A1 NAPHTHYLACETIC ACIDS HRH2, HRH1, HRH3 PTGDR2 39/4885TAS2R14 2502/4885MEN1 3010/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.